Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers

A technology of glucagon and glucagon peptide, applied in the field of glucagon analogs with enhanced solubility and stability in a physiological pH buffer, can solve problems such as troublesome methods, dangerous personnel and the like

Inactive Publication Date: 2011-06-08
INDIANA UNIV RES & TECH CORP
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the treatment is effective, the procedure is cumbersome and dangerous for some semi-comatose people

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers
  • Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers
  • Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0124] enhanced solubility

[0125] Applicants have discovered that native glucagon can be modified by introducing charges at its carboxyl terminus to enhance the solubility of the peptide while maintaining the agonist properties of the peptide. The enhanced solubility allows preparation and storage of glucagon solutions at near neutral pH. Formulating the glucagon solution at a relatively neutral pH (eg, a pH of about 6.0 to about 8.0) improves the long-term stability of the glucagon peptide.

[0126] Accordingly, one embodiment of the present invention relates to a glucagon agonist which, relative to the wild-type peptide His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr- Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr (SEQ ID NO: 1) has been modified to improve the peptide in aqueous solution Solubility, especially in the pH range of about 5.5 to about 8.0, while retaining the biological activity of the original peptide. In one embodiment, the charge is...

example

[0321] According to one embodiment, the original glucagon peptide of SEQ ID NO: 1 is modified by replacing the original amino acid at position 28 and / or 29 with a negatively charged amino acid (such as aspartic acid or glutamic acid), and optionally A negatively charged amino acid (eg, aspartic acid or glutamic acid) is optionally added to the carboxy-terminus of the peptide. In an alternative embodiment, the original glucagon peptide of SEQ ID NO: 1 is modified by replacing the original amino acid at position 29 with a positively charged amino acid (eg lysine, arginine or histidine) , and optionally add 1 or 2 positively charged amino acids (eg, lysine, arginine, or histidine) to the carboxyl terminus of the peptide. According to one embodiment, there is provided a glucagon analog with improved solubility and stability, wherein said analog comprises the amino acid sequence of SEQ ID NO: 34, with the proviso that at least one amino acid at position 28 or 29 is replaced by aci...

Embodiment 1

[0392] Glucagon Cys 17 Synthesis of (1-29) and similar MonoCys analogs

[0393] Synthesis was performed using FastBoc HBTU-activated single coupling on a modified Applied Biosystem 430A peptide synthesizer inputting 0.2 mmole Boc Thr(OBzl) Pam resin (SynChem Inc) in a 60 ml reaction tube and the following sequence.

[0394] HSQGTFTSDYSKYLDSCRAQDFVQWLMNT (SEQ ID NO: 27)

[0395] The following side chain protecting groups were used: Arg(Tos), Asp(OcHex), Asn(Xan), Cys(pMeBzl), Glu(OcHex), His(Boc), Lys(2Cl-Z), Ser(Bzl), Thr (Bzl), Trp (CHO) and Tyr (Br-Z). The completed peptidyl resin was treated with 20% piperidine / dimethylformamide to remove the Trp formyl protection, then transferred to an HF reaction tube and dried in vacuo. Add 1.0 ml p-cresol and 0.5 ml dimethyl sulfide and a magnetic stir bar. The tube was connected to HF equipment (Pennisula Labs), cooled in a dry ice / methanol bath, evacuated, and condensed into approximately 10 ml of liquid hydrogen fluoride. The r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Modified glucagon peptides are disclosed having improved solubility and / or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and / or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 61 / 073,193 filed June 17, 2008, U.S. Provisional Patent Application No. 61 / 078,165 filed July 3, 2008, and U.S. Provisional Patent Application No. 61 / 078,165 filed August 20, 2008. Provisional Patent Application No. 61 / 090,415. The disclosure of each application is expressly incorporated herein by reference in its entirety. Background technique [0003] Pre-proglucagon is a 158-amino acid precursor polypeptide that is processed in different tissues to form a number of different proglucagon-derived peptides, including glucagon, glucagon, Glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-1) and oxyntomodulin (OXM), which are involved in numerous physiological functions including glucose homeostasis, insulin secretion, gastric Emptying and intestinal growth, and regulation of food intake. Glucagon is a 29 amino acid peptide correspond...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00
CPCA61K38/00C07K14/605A61P1/00A61P23/02A61P3/00A61P3/04A61P31/10A61P3/08A61P3/10
Inventor R·D·迪马基D·L·斯米利M·迪马基J·沙贝内J·戴
Owner INDIANA UNIV RES & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com